PD-1抑制剂联合放化疗治疗局部晚期鼻咽癌的有效性和安全性研究OA
Study on the efficacy and safety of PD-1 inhibitor combined with chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma
目的 探讨程序性死亡受体-1(PD-1)抑制剂联合放化疗在局部晚期鼻咽癌中的有效性与安全性.方法 回顾性分析2019年4月至2022年6月于贵州医科大学附属肿瘤医院收治的86例局部晚期鼻咽癌患者的临床资料.采用 Kaplan-Meier法进行生存分析,Cox比例风险模型探讨各临床因素与预后的关联.结果 所有患者中位总生存(OS)时间、无进展生存(PFS)时间及无远处转移生存(DMFS)时间分别为63、58、63个月,3年 OS率、PFS率、DMFS率分别为90.8%、90.0%、90.8%.多因素Cox回归分析结果显示,治疗前EB病毒(EBV)DNA(HR=5.404,95%CI:1.218～23.976)、原发灶放疗剂量(HR=0.231,95%CI:0.075～0.707)、淋巴结放疗剂量(HR=0.231,95%CI:0.075～0.707)是局部晚期鼻咽癌患者PD-1抑制剂联合放化疗后 OS时间的独立影响因素(P<0.05).结论 PD-1抑制剂联合放化疗在局部晚期鼻咽癌中表现出良好的近期疗效,整体不良反应可耐受.
Objective To investigate the efficacy and safety of programmed cell death-1(PD-1)inhibi-tors combined with radiotherapy and chemotherapy in locally advanced nasopharyngeal carcinoma.Methods A retrospective analysis was conducted on the clinical data of 86 patients with locally advanced na-sopharyngeal carcinoma who were admitted to Cancer Hospital Affiliated to Guizhou Medical University from April 2019 to June 2022.Survival analysis was performed using the Kaplan-Meier method,and the Cox propor-tional hazards model was used to explore the association between various clinical factors and prognosis.Results The median overall survival(OS)time,progression-free survival(PFS)time,and distant metastasis-free survival(DMFS)time for all patients were 63,58,and 63 months respectively.The 3-year OS rate,PFS rate,and DMFS rate were 90.8%,90.0%,and 90.8%respectively.The results of multivariate Cox regression analysis showed that before treatment,EB virus(EBV)DNA(HR=5.404,95%CI:1.218-23.976),the ra-diotherapy dose of the primary lesion(HR=0.231,95%CI:0.075-0.707),and the radiotherapy dose of lymph nodes(HR=0.231,95%CI:0.075-0.707)were independent influencing factors for the OS time of patients with locally advanced nasopharyngeal carcinoma after PD-1 inhibitor combined with radiotherapy and chemotherapy(P<0.05).Conclusion The combination of PD-1 inhibitors with radiotherapy and chemother-apy shows excellent short-term efficacy in locally advanced nasopharyngeal carcinoma,and the overall adverse reactions are tolerable.
彭国瑶;李媛媛;金风;吴伟莉;龙金华;罗秀玲;龚修云;陈潇潇;王小艳
贵州医科大学附属医院肿瘤科,贵阳 550001||贵州医科大学附属肿瘤医院头颈肿瘤科,贵阳 550004||贵州医科大学临床医学院肿瘤学教研室,贵阳 550004贵州医科大学附属医院肿瘤科,贵阳 550001||贵州医科大学附属肿瘤医院头颈肿瘤科,贵阳 550004||贵州医科大学临床医学院肿瘤学教研室,贵阳 550004贵州医科大学附属医院肿瘤科,贵阳 550001||贵州医科大学附属肿瘤医院头颈肿瘤科,贵阳 550004||贵州医科大学临床医学院肿瘤学教研室,贵阳 550004贵州医科大学附属医院肿瘤科,贵阳 550001||贵州医科大学附属肿瘤医院头颈肿瘤科,贵阳 550004||贵州医科大学临床医学院肿瘤学教研室,贵阳 550004贵州医科大学附属医院肿瘤科,贵阳 550001||贵州医科大学附属肿瘤医院头颈肿瘤科,贵阳 550004||贵州医科大学临床医学院肿瘤学教研室,贵阳 550004贵州医科大学附属医院肿瘤科,贵阳 550001||贵州医科大学附属肿瘤医院头颈肿瘤科,贵阳 550004||贵州医科大学临床医学院肿瘤学教研室,贵阳 550004贵州医科大学附属肿瘤医院头颈肿瘤科,贵阳 550004||贵州医科大学临床医学院肿瘤学教研室,贵阳 550004贵州医科大学附属肿瘤医院头颈肿瘤科,贵阳 550004||贵州医科大学临床医学院肿瘤学教研室,贵阳 550004贵州医科大学附属肿瘤医院头颈肿瘤科,贵阳 550004
医药卫生
局部晚期鼻咽癌PD-1抑制剂预后放化疗近期疗效
locally advanced nasopharyngeal carcinomaPD-1 inhibitorprognosischemoradiotherapyshort-term efficacy
《重庆医学》 2026 (5)
977-982,989,7
贵州省卫生健康委科学技术基金项目(gzwjkj2019-1-074).
评论